Friday, July 10, 2026

Drug profile · INN

probucol

probucol (LORELCO) is a atp-binding cassette sub-family a member 1 inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — probucol
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

probucol (LORELCO) is a atp-binding cassette sub-family a member 1 inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN probucol
Brand LORELCO
Mechanism ATP-binding cassette sub-family A member 1 inhibitor
Target Phospholipid-transporting ATPase ABCA1
Route ORAL
Formulation TABLET

Mechanism of action

ATP-binding cassette sub-family A member 1 inhibitor

Primary target: Phospholipid-transporting ATPase ABCA1

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is probucol?

probucol (LORELCO) is a atp-binding cassette sub-family a member 1 inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for probucol?

LORELCO is a marketed brand name for probucol. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of probucol?

probucol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.